US20060122200A1 - Use and application of a pharmaceutical composition containing a mixture of natural- origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm- related clinical pathologies - Google Patents

Use and application of a pharmaceutical composition containing a mixture of natural- origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm- related clinical pathologies Download PDF

Info

Publication number
US20060122200A1
US20060122200A1 US11/338,156 US33815606A US2006122200A1 US 20060122200 A1 US20060122200 A1 US 20060122200A1 US 33815606 A US33815606 A US 33815606A US 2006122200 A1 US2006122200 A1 US 2006122200A1
Authority
US
United States
Prior art keywords
gonyautoxin
composition
muscle
acceptable carrier
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/338,156
Inventor
Nestor Antonio Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phytotox Ltd
Original Assignee
Phytotox Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phytotox Ltd filed Critical Phytotox Ltd
Priority to US11/338,156 priority Critical patent/US20060122200A1/en
Publication of US20060122200A1 publication Critical patent/US20060122200A1/en
Assigned to PHYTOTOX S.A. reassignment PHYTOTOX S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WILSON, NESTOR ANTONIO LAGOS
Priority to US13/487,722 priority patent/US9301958B2/en
Priority to US14/043,634 priority patent/US8889681B2/en
Priority to US14/249,914 priority patent/US8871763B2/en
Assigned to PHYTOTOX LIMITED reassignment PHYTOTOX LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PHYTOTOX S.A.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • This invention relates to pharmaceutical compositions containing heterocyclic guanidine-type compounds and uses thereof for blocking neuronal transmission. More specifically, this invention relates to tricyclic 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission.
  • Botulin A toxin is a neurotoxin that acts by chemiodenervation, or blocking the presynaptic release of the neurotransmitter acetylcholine in the neuromuscular plate, thus interfering with neuromuscular transmission, paralysing the muscle and preventing its contraction for a period of up to 4 months. Applied locally in the face of people, its effect is a facial rejuvenation that appears within 7-10 days after the toxin is applied, and has a duration of approximately 4 months. Botulin A toxin has been used for the treatment of diseases associated with muscular spasm, focal dystonia, sphincter relaxation (achalasia and anal fissure), hyperhydrosis and urinary bladder relaxation.
  • Botulin A toxin While Botulin A toxin is effective as a facial rejuvenate, it is an enzyme that is inherently unstable. This instability makes its use and handling complicated and less desirable. In fact, it requires freezing before using and must be used within four hours of opening the container. Because it is an enzyme, Botulin A toxin also generates antibodies that prevent its use in consecutive injections and can also induce an allergic response. In addition, its results are delayed 7-10 days, which is undesirable for patients wanting an immediate result. Accordingly, a need exists for a facial rejuvenate that is stable, fast-acting and that is not an enzyme.
  • compositions for interfering with neuronal transmission comprising an effective amount of at least one tricyclic 3,4-propinoperhydropurine are provided.
  • preparations for facial rejuvenation comprise an effective amount of the composition of the invention and a facial cream.
  • a third aspect of the invention methods of interfering with neuronal transmission comprising contacting a neuron with an effective amount of the pharmaceutical compositions of the invention are provided.
  • FIG. 1 is an illustration of an application pattern for the treatment of a human face.
  • compositions comprising heterocyclic guanidine-type compounds, and more specifically tricyclic 3,4-propinoperhydropurines, can be used for many cosmetic or clinical applications, without any surgery, side effects, allergies, immune rejection or hematoma.
  • the compositions of the invention may be used to treat conditions including, but not limited to blepharospasm, strabismus, focal dystonia, sphinceter relaxation (achalasia and anal fissure), hyperhydrosis, urinary bladder relaxation, muscular spasm-related pain management, muscular spasms, improved wound healing and facial wrinkling.
  • muscular relaxation is immediate, usually occurring in less than five minutes.
  • compositions of the invention comprise an effective amount of at least one tricyclic 3,4-propinoperhydropurine represented by the following structure: wherein R 1 and R 5 are independently H or OH; R 2 and R 3 are independently H or OSO 3 ; and R 4 is independently COONH 2 , OH, H, COONHSO 3 or COOCH 3 ; and a pharmacologically acceptable carrier.
  • These tricyclic 3,4-propinoperhydropurines may be purified from dinoflagellates, cyanobacterias and also may be accumulated by highly contaminated mollusks, which are also temporary muscular relaxants when locally injected. Any pharmacologically acceptable carrier may be used, including but not limited to water.
  • the compounds of the invention are generally diluted in a solution of acetic acid or 0.09% sodium chloride.
  • an effective amount is that amount sufficient to interfere with neuronal transmission by blocking the presynaptic release of the neurotransmitter acetylcholine in the neuromuscular plate, thus interfering with transmission, paralysing the muscle and preventing it from contracting, or producing a relaxation of contracted muscles.
  • an effective amount of the compositions of the invention may be a 100 to 800 microliter dose of forty units per milliliter solution of tricyclic 3,4-propinoperhydropurines.
  • the unit of activity is the amount of the composition of the invention necessary to block the muscular contractions of the crural biceps of a mouse leg for 1.5 to 2.0 hours.
  • the compounds of the invention are generally diluted with a 10 mM (millimolar), pH 4 solution of acetic acid.
  • the compositions of the invention comprise 40 units per milliliter of a 10 mM, pH 4 solution of acetic acid.
  • the pharmaceutical compositions of the invention comprise Saxitoxin.
  • the pharmaceutical compositions of the invention comprise Gonyautoxin 2.
  • the pharmaceutical compositions of the invention comprise Gonyautoxin 3.
  • the pharmaceutical compositions of the invention comprise Gonyautoxin 4.
  • the pharmaceutical compositions of the invention comprise Gonyautoxin 5.
  • the pharmaceutical compositions of the invention comprise neoSaxtoxin.
  • the pharmaceutical compositions of the invention comprise Gonyautoxin 1.
  • the pharmaceutical compositions of the invention comprise Decarbamoyl-Saxitoxin.
  • TABLE 1 Tricyclic 3,4-propinoperhydropurines Compound R 1 R 2 R 3 R 4 R 5 Saxitoxin H H H COONH 2 OH neoSaxitoxin OH H H COONH 2 OH Decarbamoyl- OH H H OH OH Saxitoxin Gonyautoxin 1 OH H OSO ⁇ 3 COONH 2 OH Gonyautoxin 2 H H OSO ⁇ 3 COONH 2 OH Gonyautoxin 3 H OSO ⁇ 3 H COONH 2 OH Gonyautoxin 4 OH OSO ⁇ 3 H COONH 2 OH Gonyautoxin 5 H H H COONHSO ⁇ 3 OH
  • the pharmaceutical compositions comprise a mixture of tricyclic 3,4-propinoperhydropurines.
  • the compounds are purified and used individually and/or mixed together.
  • the pharmaceutical compositions of the invention comprise a mixture of Gonyautoxin 2, Gonyautoxin 3, and Saxitoxin.
  • the pharmaceutical compositions of the invention comprise a mixture of Gonyautoxin 4, Gonyautoxin 1, Gonyautoxin 5, Gonyautoxin 3 and Gonyautoxin 2.
  • the pharmaceutical compositions of the invention comprise neoSaxitoxin and Gonyautoxin 2.
  • compositions of the invention comprise a mixture of Saxitoxin, neoSaxitoxin; Decarbamoyl-Saxitoxin, Gonyautoxin 3 and Gonyautoxin 2. It should be understood by those of skill in the art that other mixtures and combinations of tricyclic 3,4-propinoperhydropurines are within the scope of this invention.
  • the compounds of the invention are used in combination with an effective amount of Botulin A toxin.
  • the pharmaceutical compositions of the invention comprise an effective amount of Botulin A toxin and an effective amount of at least one tricyclic 3,4-propinoperhydropurine.
  • the combination may be used in any cosmetic or clinical application in which the compounds of the invention, or Botulin A toxin are used, for example, blepharospasm, strabismus, focal dystonia, sphincter relaxation (achalasia and anal fissure), hyperhydrosis, urinary bladder relaxation, muscular spasm-related pain management, muscular spasms, improved wound healing, and facial wrinkle removal.
  • compositions of the invention may be used for many cosmetic and clinical applications including, but not limited to blepharospasm, strabismus, focal dystonia, sphincter relaxation (achalasia and anal fissure), hyperhydrosis, urinary bladder relaxation, muscular spasm-related pain management, muscular spasms, improved wound healing, and facial wrinkle removal.
  • the pharmaceutical compositions of the invention are applied locally in the form of preparations.
  • an effective amount of the pharmaceutical compositions of the invention are added to a facial cream complete with its coadjuvants.
  • these preparations are stable at room temperature, do not require refrigeration, are sterilizable, do not generate antibodies, are not peptide in nature, act immediately, and may be injected repeatedly without any side effects.
  • these compounds when applied locally, these compounds carry out their antispasmodic action by blocking the spreading of nervous impulse, or neuronal transmission, by reversibly binding to the sole biological molecular receptor, i.e. the voltage gated sodium channel, present in all neurons and excitable cells. By binding to this channel, there is no entry of sodium to the neuronal cell; depolarization does not occur and, therefore, propagation of the impulse is stopped.
  • This action mechanism blocks the presynaptic release of the neurotransmitter acetylcholine in the neuromuscular plate, thus interfering with neuromuscular transmission, paralysing the muscle and preventing it from contracting, or producing a relaxation of muscles contracted by pathological problems.
  • This mechanism is particularly efficient for cosmetic purposes, as it does not let some facial muscles contract, all of them associated with and responsible for the formation of wrinkles, thus producing the sought-after effect of facial rejuvenation.
  • the pharmaceutical preparations of the invention are applied locally around the muscle that is to be paralysed or prevented from contracting.
  • the application should be in amounts of no more than one milliliter in different places around the muscle, particularly around the areas of greatest innervations.
  • the unit of activity is the amount of the compositions of the invention necessary to block the contractions of the crural biceps of a mouse leg for 1.5 to 2 hours.
  • the preferred dosage rate is 100 to 800 microliters per injected point, depending on the size, irrigation and anatomical location of the muscle, while maintaining a concentration of 20-40 units/milliliter.
  • the effect is immediately apparent, generally occuring a maximum of thirty seconds after injection. The maximum effect may be seen within 15 minutes.
  • the injection may be accomplished by using a 1 milliliter, tuberculin-type disposable syringe with a twenty-seven to thirty gauge needle. In the case of strabismus, a dose of twenty to forty units in a volume of 50-100 microliters may be injected in the orbicular muscle.
  • Use of the pharmaceutical preparations of the invention is limited to individuals over twelve years old. There is no contraindication for pregnant women.
  • a photographic record is made of the person to be treated, first with her face resting and relaxed, and then, frowning and producing a maximum facial contraction. The person then places ice on their forehead and on the two lateral zones where the preparation is to be injected. With reference to FIG. 2 , the application should follow a specific pattern.
  • a volume is injected alongside each black-dot injection point shown in FIG. 2 .
  • a pharmaceutical composition comprising a (2:1:1 volume/volume) mixture of Gonyautoxin 2, Gonyautoxin 3 and Saxitoxin mixture is applied at a dose of 40 units/milliliter. Each injection is made with a 1 milliliter, tuberculin-type disposable syringe with a 27-30 gauge needle. After injecting, the point of injection is disinfected with a gauze soaked in bi-alcohol or in any other disinfectant. The total amount required to complete the face treatment is 1.7 milliliters.
  • the expected result is an immediate inability to frown and to show lines when the face is resting.
  • the person experiences a feeling of facial stretching similar to that felt when applying a facial cream mask.
  • ice is applied on the injected zones for five minutes.
  • the patient gets used to the feeling of facial stretching.
  • the person walks out with no discernible wrinkles, a rejuvenated facial look, no face marks or hematoma, and completely normal.
  • the face recovers its normal color within twenty minutes, depending on how relaxed the injected patient has become.
  • the whole application procedure takes ten minutes at the most, and produces a very slight pain from the needle and the injected solution. The pain disappears as soon as the syringe is withdrawn.
  • the patient may be checked the next day and every fifteen days thereafter. At this dose, the effect lasts for one month. After the first month, the treatment may be repeated as often as necessary.

Abstract

Pharmaceutical compositions comprising tricyclic 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission are provided.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application claims priority under the Paris Convention for the Protection of Industrial Property to Chilean Patent Application Number 2764-2001, filed on Nov. 15, 2001 in the Department of Industrial Property in the Republic of Chile.
    • STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
  • Not applicable.
    • REFERENCE TO MICROFICHE APPENDIX
  • Not applicable.
    • FIELD OF THE INVENTION
  • This invention relates to pharmaceutical compositions containing heterocyclic guanidine-type compounds and uses thereof for blocking neuronal transmission. More specifically, this invention relates to tricyclic 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission.
    • BACKGROUND OF THE INVENTION
  • The presence of wrinkles in the neck and face of people are seen as negative aesthetic effects by social groups. These marks reflect face aging and increase the subjective awareness of the age of people. Since the beginning of civilization, natural or synthetic chemical compounds have been used and procedures have been developed (i.e. plastic surgery) to alleviate this problem. For example, plastic surgeons and cosmetic centers have been experimenting with and using Botulin A toxin as a pharmaceutical preparation that produces facial rejuvenation by removing face wrinkles. Botulin A toxin is a neurotoxin that acts by chemiodenervation, or blocking the presynaptic release of the neurotransmitter acetylcholine in the neuromuscular plate, thus interfering with neuromuscular transmission, paralysing the muscle and preventing its contraction for a period of up to 4 months. Applied locally in the face of people, its effect is a facial rejuvenation that appears within 7-10 days after the toxin is applied, and has a duration of approximately 4 months. Botulin A toxin has been used for the treatment of diseases associated with muscular spasm, focal dystonia, sphincter relaxation (achalasia and anal fissure), hyperhydrosis and urinary bladder relaxation.
  • While Botulin A toxin is effective as a facial rejuvenate, it is an enzyme that is inherently unstable. This instability makes its use and handling complicated and less desirable. In fact, it requires freezing before using and must be used within four hours of opening the container. Because it is an enzyme, Botulin A toxin also generates antibodies that prevent its use in consecutive injections and can also induce an allergic response. In addition, its results are delayed 7-10 days, which is undesirable for patients wanting an immediate result. Accordingly, a need exists for a facial rejuvenate that is stable, fast-acting and that is not an enzyme.
    • SUMMARY OF THE INVENTION
  • In accordance with the objects of the invention, novel compositions and methods are provided. In one aspect of the invention, pharmaceutical compositions for interfering with neuronal transmission comprising an effective amount of at least one tricyclic 3,4-propinoperhydropurine are provided.
  • In a second aspect of the invention, preparations for facial rejuvenation are provided that comprise an effective amount of the composition of the invention and a facial cream.
  • In a third aspect of the invention, methods of interfering with neuronal transmission comprising contacting a neuron with an effective amount of the pharmaceutical compositions of the invention are provided.
  • In a forth aspect of the invention, methods of interfering with muscle contracting comprising contacting a muscle with an effective amount of the composition of the invention are Provided.
    • DETAILED DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is an illustration of an application pattern for the treatment of a human face.
    • DETAILED DESCRIPTION OF THE INVENTION
  • In accordance with the present invention, it has been discovered that compositions comprising heterocyclic guanidine-type compounds, and more specifically tricyclic 3,4-propinoperhydropurines, can be used for many cosmetic or clinical applications, without any surgery, side effects, allergies, immune rejection or hematoma. The compositions of the invention may be used to treat conditions including, but not limited to blepharospasm, strabismus, focal dystonia, sphinceter relaxation (achalasia and anal fissure), hyperhydrosis, urinary bladder relaxation, muscular spasm-related pain management, muscular spasms, improved wound healing and facial wrinkling. In accordance with the present invention, muscular relaxation is immediate, usually occurring in less than five minutes.
  • The compositions of the invention comprise an effective amount of at least one tricyclic 3,4-propinoperhydropurine represented by the following structure:
    Figure US20060122200A1-20060608-C00001
    wherein R1 and R5 are independently H or OH; R2 and R3 are independently H or OSO3; and R4 is independently COONH2, OH, H, COONHSO3 or COOCH3; and a pharmacologically acceptable carrier. These tricyclic 3,4-propinoperhydropurines may be purified from dinoflagellates, cyanobacterias and also may be accumulated by highly contaminated mollusks, which are also temporary muscular relaxants when locally injected. Any pharmacologically acceptable carrier may be used, including but not limited to water. The compounds of the invention are generally diluted in a solution of acetic acid or 0.09% sodium chloride.
  • As used herein, “an effective amount” is that amount sufficient to interfere with neuronal transmission by blocking the presynaptic release of the neurotransmitter acetylcholine in the neuromuscular plate, thus interfering with transmission, paralysing the muscle and preventing it from contracting, or producing a relaxation of contracted muscles. For example, an effective amount of the compositions of the invention may be a 100 to 800 microliter dose of forty units per milliliter solution of tricyclic 3,4-propinoperhydropurines. The unit of activity is the amount of the composition of the invention necessary to block the muscular contractions of the crural biceps of a mouse leg for 1.5 to 2.0 hours. The compounds of the invention are generally diluted with a 10 mM (millimolar), pH 4 solution of acetic acid. In one specific embodiment of the invention, the compositions of the invention comprise 40 units per milliliter of a 10 mM, pH 4 solution of acetic acid.
  • In one embodiment of the invention, and with reference to Table 1 below, the pharmaceutical compositions of the invention comprise Saxitoxin. In a second embodiment of the invention, the pharmaceutical compositions of the invention comprise Gonyautoxin 2. In a third embodiment of the invention, the pharmaceutical compositions of the invention comprise Gonyautoxin 3. In a forth embodiment of the invention, the pharmaceutical compositions of the invention comprise Gonyautoxin 4. In a fifth embodiment of the invention, the pharmaceutical compositions of the invention comprise Gonyautoxin 5. In a sixth embodiment of the invention, the pharmaceutical compositions of the invention comprise neoSaxtoxin. In a seventh embodiment of the invention, the pharmaceutical compositions of the invention comprise Gonyautoxin 1. In an eighth embodiment of the invention, the pharmaceutical compositions of the invention comprise Decarbamoyl-Saxitoxin.
    TABLE 1
    Tricyclic 3,4-propinoperhydropurines
    Compound R1 R2 R3 R4 R5
    Saxitoxin H H H COONH2 OH
    neoSaxitoxin OH H H COONH2 OH
    Decarbamoyl- OH H H OH OH
    Saxitoxin
    Gonyautoxin 1 OH H OSO− 3 COONH2 OH
    Gonyautoxin 2 H H OSO− 3 COONH2 OH
    Gonyautoxin 3 H OSO− 3 H COONH2 OH
    Gonyautoxin 4 OH OSO− 3 H COONH2 OH
    Gonyautoxin 5 H H H COONHSO− 3 OH
  • In specific embodiments of the invention, the pharmaceutical compositions comprise a mixture of tricyclic 3,4-propinoperhydropurines. The compounds are purified and used individually and/or mixed together. In one preferred embodiment, the pharmaceutical compositions of the invention comprise a mixture of Gonyautoxin 2, Gonyautoxin 3, and Saxitoxin. In another preferred embodiment, the pharmaceutical compositions of the invention comprise a mixture of Gonyautoxin 4, Gonyautoxin 1, Gonyautoxin 5, Gonyautoxin 3 and Gonyautoxin 2. In yet another preferred embodiment, the pharmaceutical compositions of the invention comprise neoSaxitoxin and Gonyautoxin 2. In still another preferred embodiment, the pharmaceutical compositions of the invention comprise a mixture of Saxitoxin, neoSaxitoxin; Decarbamoyl-Saxitoxin, Gonyautoxin 3 and Gonyautoxin 2. It should be understood by those of skill in the art that other mixtures and combinations of tricyclic 3,4-propinoperhydropurines are within the scope of this invention.
  • In one embodiment of the invention, the compounds of the invention are used in combination with an effective amount of Botulin A toxin. In this embodiment, the pharmaceutical compositions of the invention comprise an effective amount of Botulin A toxin and an effective amount of at least one tricyclic 3,4-propinoperhydropurine. The combination may be used in any cosmetic or clinical application in which the compounds of the invention, or Botulin A toxin are used, for example, blepharospasm, strabismus, focal dystonia, sphincter relaxation (achalasia and anal fissure), hyperhydrosis, urinary bladder relaxation, muscular spasm-related pain management, muscular spasms, improved wound healing, and facial wrinkle removal.
  • These pharmaceutical compositions of the invention may be used for many cosmetic and clinical applications including, but not limited to blepharospasm, strabismus, focal dystonia, sphincter relaxation (achalasia and anal fissure), hyperhydrosis, urinary bladder relaxation, muscular spasm-related pain management, muscular spasms, improved wound healing, and facial wrinkle removal. Generally, the pharmaceutical compositions of the invention are applied locally in the form of preparations. To form preparations, an effective amount of the pharmaceutical compositions of the invention are added to a facial cream complete with its coadjuvants. Unlike Botulin A toxin, these preparations are stable at room temperature, do not require refrigeration, are sterilizable, do not generate antibodies, are not peptide in nature, act immediately, and may be injected repeatedly without any side effects.
  • Without being bound by theory, when applied locally, these compounds carry out their antispasmodic action by blocking the spreading of nervous impulse, or neuronal transmission, by reversibly binding to the sole biological molecular receptor, i.e. the voltage gated sodium channel, present in all neurons and excitable cells. By binding to this channel, there is no entry of sodium to the neuronal cell; depolarization does not occur and, therefore, propagation of the impulse is stopped. This action mechanism blocks the presynaptic release of the neurotransmitter acetylcholine in the neuromuscular plate, thus interfering with neuromuscular transmission, paralysing the muscle and preventing it from contracting, or producing a relaxation of muscles contracted by pathological problems. This mechanism is particularly efficient for cosmetic purposes, as it does not let some facial muscles contract, all of them associated with and responsible for the formation of wrinkles, thus producing the sought-after effect of facial rejuvenation.
  • The pharmaceutical preparations of the invention are applied locally around the muscle that is to be paralysed or prevented from contracting. The application should be in amounts of no more than one milliliter in different places around the muscle, particularly around the areas of greatest innervations. The unit of activity is the amount of the compositions of the invention necessary to block the contractions of the crural biceps of a mouse leg for 1.5 to 2 hours. The preferred dosage rate is 100 to 800 microliters per injected point, depending on the size, irrigation and anatomical location of the muscle, while maintaining a concentration of 20-40 units/milliliter. The effect is immediately apparent, generally occuring a maximum of thirty seconds after injection. The maximum effect may be seen within 15 minutes. Its effective duration depends on the dose administered, the muscle in question, as well as the volume and specific composition administered. This is the pattern for all clinical applications and pathologies. The injection may be accomplished by using a 1 milliliter, tuberculin-type disposable syringe with a twenty-seven to thirty gauge needle. In the case of strabismus, a dose of twenty to forty units in a volume of 50-100 microliters may be injected in the orbicular muscle. Use of the pharmaceutical preparations of the invention is limited to individuals over twelve years old. There is no contraindication for pregnant women.
  • The advantageous properties of this invention can be observed by reference to the following example, which is meant to illustrate, and not limit, the invention in any way.
    • EXAMPLE
  • Before the application, a photographic record is made of the person to be treated, first with her face resting and relaxed, and then, frowning and producing a maximum facial contraction. The person then places ice on their forehead and on the two lateral zones where the preparation is to be injected. With reference to FIG. 2, the application should follow a specific pattern. A volume is injected alongside each black-dot injection point shown in FIG. 2. A pharmaceutical composition comprising a (2:1:1 volume/volume) mixture of Gonyautoxin 2, Gonyautoxin 3 and Saxitoxin mixture is applied at a dose of 40 units/milliliter. Each injection is made with a 1 milliliter, tuberculin-type disposable syringe with a 27-30 gauge needle. After injecting, the point of injection is disinfected with a gauze soaked in bi-alcohol or in any other disinfectant. The total amount required to complete the face treatment is 1.7 milliliters.
  • The expected result is an immediate inability to frown and to show lines when the face is resting. The person experiences a feeling of facial stretching similar to that felt when applying a facial cream mask. After that, ice is applied on the injected zones for five minutes. Thirty minutes after the application, the patient gets used to the feeling of facial stretching. At that time, the person walks out with no discernible wrinkles, a rejuvenated facial look, no face marks or hematoma, and completely normal. The face recovers its normal color within twenty minutes, depending on how relaxed the injected patient has become. The whole application procedure takes ten minutes at the most, and produces a very slight pain from the needle and the injected solution. The pain disappears as soon as the syringe is withdrawn. There are no traumas of any kind, nor any sequelae. The patient may be checked the next day and every fifteen days thereafter. At this dose, the effect lasts for one month. After the first month, the treatment may be repeated as often as necessary.
  • In view of the above, it will be seen that all the objects and features of the present invention are achieved, and other advantageous results obtained. The examples and description of the invention contained herein is illustrative only, and is not intended in a limiting sense.

Claims (31)

1. A method of interfering with neuronal transmission comprising contacting a neuron with an effective amount of the composition comprising at least one compound selected from the group consisting of Gonyautoxin 1, Gonyautoxin 2, Gonyautoxin 3, Gonyautoxin 4 and Gonyautoxin 5; and a pharmaceutically acceptable carrier.
2. The method of claim 1, wherein the composition comprises a mixture of at least two compounds selected from the group consisting of Gonyautoxin 1, Gonyautoxin 2, Gonyautoxin 3, Gonyautoxin 4 and Gonyautoxin 5.
3. The method of claim 1, wherein the composition further comprises Botulin A toxin.
4. The method of claim 1, wherein about 100 to about 800 microliters of said composition is contacted with said neuron.
5. The method of claim 1, wherein less than one milliliter of said composition is contacted with said neuron.
6. The method of claim 1, wherein said contacting step comprises injecting the composition into an area proximate to the neuron.
7. The method of claim 1, wherein said composition comprises about 20 to about 40 units of the compound per milliliter of total composition.
8. The method of claim 1, wherein the carrier is acetic acid.
9. The method of claim 1, wherein said neuron is innervating a muscle.
10. The method of claim 9, wherein said muscle is inside a human face.
11. A method as claimed in claim 1, wherein the composition consists of Gonyautoxin 2, Gonyautoxin 3 and a pharmaceutically acceptable carrier.
12. A method interfering with muscle contraction comprising contacting a muscle with an effective amount of a composition comprising at least one compound selected from the group consisting of Gonyautoxin 1, Gonyautoxin 2, Gonyautoxin 3, Gonyautoxin 4, and Gonyautoxin 5; and a pharmaceutically acceptable carrier.
13. The method of claim 12, wherein the composition comprises a mixture of Gonyautoxin 2 and Gonyautoxin 3.
14. The method of claim 12, wherein the composition further comprises Botulin A toxin.
15. The method of claim 12, wherein the composition comprises about 20 to about 40 units of the compound per milliliter of the carrier.
16. The method of claim 12, wherein the carrier is acetic acid.
17. The method of claim 12, wherein the composition comprises about twenty to about forty units of the compound per milliliter of total composition.
18. The method of claim 12, wherein contacting an effective amount of the composition with a muscle comprises injecting the composition into an area proximate to the muscle.
19. The method of claim 18, wherein no more than one milliliter: of the composition is injected into an area proximate to the muscle per injection point.
20. The method of claim 19, wherein about 100 to about 800 microliters of the composition is injected into an area proximate to the muscle per injection point.
21. The method of claim 12, wherein the muscle is inside a human face.
22. The method of claim 12, wherein the composition consists of Gonyautoxin 2, Gonyautoxin 3 and a pharmacologically acceptable carrier.
23. A pharmaceutical composition for interfering with neuronal transmission, the composition consisting of an effective amount of Gonyautoxin 2, Gonyautoxin 3 and a pharmacologically acceptable carrier.
24. The composition of claim 23, wherein the composition includes about twenty to about forty units of the Gonyautoxin 2 and Gonyautoxin 3 per milliliter of total solution.
25. The composition of claim 23, wherein the pharmaceutically acceptable carrier is acetic acid.
26. A preparation for facial rejuvenation comprising an effective amount of a composition comprising at least one compound selected from the group consisting of Gonyautoxin 1, Gonyautoxin 2, Gonyautoxin 3, Gonyautoxin 4, and Gonyautoxin 5; and a facial cream.
27. The preparation of claim 26, wherein said composition comprises about twenty to about forty units of the at least one compound per milliliter of total solution.
28. The preparation of claim 26, further comprising a pharmaceutically acceptable carrier.
29. The preparation of claim 28, wherein said pharmaceutically acceptable carrier is acetic acid.
30. The preparation of claim 26 wherein the composition consists of Gonyautoxin 2, Gonyautoxin 3 and a facial cream.
31. The preparation of claim 26, further comprising Botulin A toxin.
US11/338,156 2001-11-15 2006-01-24 Use and application of a pharmaceutical composition containing a mixture of natural- origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm- related clinical pathologies Abandoned US20060122200A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US11/338,156 US20060122200A1 (en) 2001-11-15 2006-01-24 Use and application of a pharmaceutical composition containing a mixture of natural- origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm- related clinical pathologies
US13/487,722 US9301958B2 (en) 2001-11-15 2012-06-04 Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine
US14/043,634 US8889681B2 (en) 2001-11-15 2013-10-01 Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm-related clinical pathologies
US14/249,914 US8871763B2 (en) 2001-11-15 2014-04-10 Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm- related clinical pathologies

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CL2764-2001 2001-11-15
CL27642001 2001-11-15
US10/294,288 US20030100574A1 (en) 2001-11-15 2002-11-14 Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm-related clinical pathologies
US11/338,156 US20060122200A1 (en) 2001-11-15 2006-01-24 Use and application of a pharmaceutical composition containing a mixture of natural- origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm- related clinical pathologies

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/294,288 Division US20030100574A1 (en) 2001-11-15 2002-11-14 Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm-related clinical pathologies

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/487,722 Continuation US9301958B2 (en) 2001-11-15 2012-06-04 Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine
US14/043,634 Continuation US8889681B2 (en) 2001-11-15 2013-10-01 Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm-related clinical pathologies

Publications (1)

Publication Number Publication Date
US20060122200A1 true US20060122200A1 (en) 2006-06-08

Family

ID=4574581

Family Applications (5)

Application Number Title Priority Date Filing Date
US10/294,288 Abandoned US20030100574A1 (en) 2001-11-15 2002-11-14 Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm-related clinical pathologies
US11/338,156 Abandoned US20060122200A1 (en) 2001-11-15 2006-01-24 Use and application of a pharmaceutical composition containing a mixture of natural- origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm- related clinical pathologies
US13/487,722 Expired - Lifetime US9301958B2 (en) 2001-11-15 2012-06-04 Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine
US14/043,634 Expired - Fee Related US8889681B2 (en) 2001-11-15 2013-10-01 Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm-related clinical pathologies
US14/249,914 Expired - Fee Related US8871763B2 (en) 2001-11-15 2014-04-10 Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm- related clinical pathologies

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/294,288 Abandoned US20030100574A1 (en) 2001-11-15 2002-11-14 Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm-related clinical pathologies

Family Applications After (3)

Application Number Title Priority Date Filing Date
US13/487,722 Expired - Lifetime US9301958B2 (en) 2001-11-15 2012-06-04 Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine
US14/043,634 Expired - Fee Related US8889681B2 (en) 2001-11-15 2013-10-01 Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm-related clinical pathologies
US14/249,914 Expired - Fee Related US8871763B2 (en) 2001-11-15 2014-04-10 Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm- related clinical pathologies

Country Status (18)

Country Link
US (5) US20030100574A1 (en)
EP (1) EP1443932B1 (en)
JP (2) JP5331959B2 (en)
KR (2) KR20100135884A (en)
CN (2) CN102349914B (en)
AU (1) AU2002348370B8 (en)
BR (1) BR0214126A (en)
CA (1) CA2466697C (en)
EA (1) EA006739B1 (en)
ES (1) ES2401570T3 (en)
HU (1) HUP0402268A2 (en)
IL (1) IL161949A0 (en)
MX (1) MXPA04004543A (en)
NO (1) NO20042475L (en)
NZ (1) NZ533309A (en)
PL (1) PL370686A1 (en)
WO (1) WO2003047589A1 (en)
ZA (1) ZA200403765B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070280970A1 (en) * 2004-05-07 2007-12-06 Phytotox Limited Methods of Treating Wounds With Gonyautoxins
US20080045553A1 (en) * 2004-05-07 2008-02-21 Phytotox Limited Transdermal Administration of Phycotoxins
US20090189226A1 (en) * 2008-01-28 2009-07-30 Yasue Yamamoto Electrical fuse circuit

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102349914B (en) * 2001-11-15 2015-01-28 微观藻类公司 Pharmaceutical compositions containing 3, 4-propinoperhydropurines and uses thereof for blocking neuronal transmission
AU2006243644A1 (en) * 2005-05-05 2006-11-09 Phytotox Limited Use of phycotoxins in veterinary applications
CL2009000723A1 (en) * 2009-03-24 2009-06-19 Proteus Sa Industrial purification method of biologically active phycotoxins comprising providing an adequate amount of a source of phycotoxins such as the cultivation of a cyanobacterial clone.
US9174999B2 (en) * 2009-05-07 2015-11-03 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for studying, imaging, and treating pain
WO2011098539A1 (en) * 2010-02-10 2011-08-18 Phytotox Limited Treatment of loss of sense of touch with saxitoxin derivatives
HUE042711T2 (en) 2013-03-15 2019-07-29 Childrens Medical Ct Corp Neosaxitoxin combination formulations for prolonged local anesthesia
GB201602576D0 (en) 2016-02-12 2016-03-30 Bergen Teknologioverforing As Process

Citations (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957966A (en) * 1972-05-19 1976-05-18 Gaf Corporation Stabilized vitamin food coatings
US4001413A (en) * 1973-06-12 1977-01-04 Astra Pharmaceutical Products, Inc. Pharmaceutical local anesthetic composition employing saxitoxin
US4029794A (en) * 1973-06-12 1977-06-14 Astra Pharmaceutical Products, Inc. Pharmaceutical local anesthetic composition
US5183462A (en) * 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US5504117A (en) * 1994-05-27 1996-04-02 Neptune Pharmaceutical Corporation Pharmacologic preparation for the treatment of anal disorders
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
US5714468A (en) * 1994-05-09 1998-02-03 Binder; William J. Method for reduction of migraine headache pain
US5721215A (en) * 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US5774205A (en) * 1995-07-21 1998-06-30 Canon Kabushiki Kaisha Exposure and method which tests optical characteristics of optical elements in a projection lens system prior to exposure
US5837265A (en) * 1996-03-08 1998-11-17 The Regents Of The University Of California Chemically-modified clostridiatoxin with improved properties
US5908746A (en) * 1995-06-09 1999-06-01 Nisshinbo Industries, Inc. Method for analyzing biologically active substances
US6030974A (en) * 1997-04-02 2000-02-29 The Regents Of The University Of California Method of anesthesia
US6117877A (en) * 1998-02-27 2000-09-12 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
US6143306A (en) * 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6187756B1 (en) * 1996-09-05 2001-02-13 The Massachusetts Institute Of Technology Composition and methods for treatment of neurological disorders and neurodegenerative diseases
US6261572B1 (en) * 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US6299893B1 (en) * 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20010046962A1 (en) * 1991-09-24 2001-11-29 Allergan Inc. Method and compositions for the treatment of cerebral palsy
US6326020B1 (en) * 1997-05-16 2001-12-04 Children's Medical Center Corporation Local anesthetic formulations
US20010053369A1 (en) * 2000-06-14 2001-12-20 Stephen Donovan Epilepsy treatment
US20020025327A1 (en) * 1997-07-15 2002-02-28 University Technology Corporation Use of neurotoxin therapy for treatment of urologic and related disorders
US6358926B2 (en) * 1999-10-13 2002-03-19 Allergan Sales, Inc. Neurotoxin therapy for inner ear disorders
US6407088B1 (en) * 2000-09-18 2002-06-18 Wex Medical Instrumentation Co., Ltd. Method of analgesia
US20020086036A1 (en) * 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
US6416765B1 (en) * 2000-01-11 2002-07-09 Allergan Sales, Inc. Neurotoxin therapy for diabetes
US6447787B1 (en) * 1998-10-27 2002-09-10 Mayo Foundation For Medical Education And Research Methods for enhancing wound healing
US20020161013A1 (en) * 2001-04-25 2002-10-31 Wex Medical Intrumentation Co., Ltd. Method of local anesthesia and analgesia
US20020176872A1 (en) * 2000-04-14 2002-11-28 Allergan Sales, Inc. Pain treatment by peripheral administration of a neurotoxin
US20020192240A1 (en) * 2000-10-04 2002-12-19 Allergan Sales, Inc. Therapy for injured muscles
US20020198226A1 (en) * 2001-05-18 2002-12-26 Baoshan Ku Analgesic composition and method
US6559154B2 (en) * 2000-11-22 2003-05-06 Nanning Maple Leaf Pharmaceutical Co., Ltd. Composition of sodium channel blocking compound
US6599906B1 (en) * 2000-09-18 2003-07-29 Wex Medical Instrumentation Co., Ltd. Method of local anesthesia and analgesia
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1081034C (en) * 1997-03-07 2002-03-20 潘心富 Medicine of diguanidino-prine-hydride compounds for giving up drug-taking
US6432986B2 (en) * 1997-07-21 2002-08-13 Bruce H. Levin Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
US6261573B1 (en) * 1998-10-30 2001-07-17 Avant Immunotherapeutics, Inc. Immunoadjuvants
US6183747B1 (en) * 1999-07-14 2001-02-06 Kaijun Ren Use of plant Momordica charactia extracts for treatment of acne acid
WO2001036588A2 (en) * 1999-11-16 2001-05-25 The General Hospital Corporation Fusion proteins that specifically inhibit protein synthesis in neuronal cells
CN1240702C (en) 2000-09-18 2006-02-08 威克斯医药有限公司 Process for extracting tetrodosin with high output rate
CN102349914B (en) * 2001-11-15 2015-01-28 微观藻类公司 Pharmaceutical compositions containing 3, 4-propinoperhydropurines and uses thereof for blocking neuronal transmission
CN1194693C (en) * 2002-01-11 2005-03-30 中国科学院海洋研究所 Application of paralytic PSP toxin in preparing antalgesic medicine

Patent Citations (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957966A (en) * 1972-05-19 1976-05-18 Gaf Corporation Stabilized vitamin food coatings
US4001413A (en) * 1973-06-12 1977-01-04 Astra Pharmaceutical Products, Inc. Pharmaceutical local anesthetic composition employing saxitoxin
US4029794A (en) * 1973-06-12 1977-06-14 Astra Pharmaceutical Products, Inc. Pharmaceutical local anesthetic composition
US5183462A (en) * 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5298019A (en) * 1990-08-21 1994-03-29 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US20020142010A1 (en) * 1991-09-24 2002-10-03 Allergan Method and compositions for the treatment of cerebral palsy
US20010046962A1 (en) * 1991-09-24 2001-11-29 Allergan Inc. Method and compositions for the treatment of cerebral palsy
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US5714468A (en) * 1994-05-09 1998-02-03 Binder; William J. Method for reduction of migraine headache pain
US5504117A (en) * 1994-05-27 1996-04-02 Neptune Pharmaceutical Corporation Pharmacologic preparation for the treatment of anal disorders
US5908746A (en) * 1995-06-09 1999-06-01 Nisshinbo Industries, Inc. Method for analyzing biologically active substances
US5774205A (en) * 1995-07-21 1998-06-30 Canon Kabushiki Kaisha Exposure and method which tests optical characteristics of optical elements in a projection lens system prior to exposure
US5837265A (en) * 1996-03-08 1998-11-17 The Regents Of The University Of California Chemically-modified clostridiatoxin with improved properties
US5721215A (en) * 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US6187756B1 (en) * 1996-09-05 2001-02-13 The Massachusetts Institute Of Technology Composition and methods for treatment of neurological disorders and neurodegenerative diseases
US6030974A (en) * 1997-04-02 2000-02-29 The Regents Of The University Of California Method of anesthesia
US6326020B1 (en) * 1997-05-16 2001-12-04 Children's Medical Center Corporation Local anesthetic formulations
US20020025327A1 (en) * 1997-07-15 2002-02-28 University Technology Corporation Use of neurotoxin therapy for treatment of urologic and related disorders
US6117877A (en) * 1998-02-27 2000-09-12 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
US20030036502A1 (en) * 1998-10-27 2003-02-20 Gassner Holger G. Methods for enhancing wound healing
US6447787B1 (en) * 1998-10-27 2002-09-10 Mayo Foundation For Medical Education And Research Methods for enhancing wound healing
US6358926B2 (en) * 1999-10-13 2002-03-19 Allergan Sales, Inc. Neurotoxin therapy for inner ear disorders
US6143306A (en) * 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6416765B1 (en) * 2000-01-11 2002-07-09 Allergan Sales, Inc. Neurotoxin therapy for diabetes
US6261572B1 (en) * 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US20020176872A1 (en) * 2000-04-14 2002-11-28 Allergan Sales, Inc. Pain treatment by peripheral administration of a neurotoxin
US20040028706A1 (en) * 2000-04-14 2004-02-12 Aoki Kei Roger Neuralgia pain treatment by peripheral administration of a neurotoxin
US20040018213A1 (en) * 2000-04-14 2004-01-29 Allergan Inc. Pain treatment by peripheral administration of a neurotoxin
US6299893B1 (en) * 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20010053369A1 (en) * 2000-06-14 2001-12-20 Stephen Donovan Epilepsy treatment
US20010053370A1 (en) * 2000-06-14 2001-12-20 Stephen Donovan Parkinson's disease treatment
US6407088B1 (en) * 2000-09-18 2002-06-18 Wex Medical Instrumentation Co., Ltd. Method of analgesia
US6599906B1 (en) * 2000-09-18 2003-07-29 Wex Medical Instrumentation Co., Ltd. Method of local anesthesia and analgesia
US20020192240A1 (en) * 2000-10-04 2002-12-19 Allergan Sales, Inc. Therapy for injured muscles
US6559154B2 (en) * 2000-11-22 2003-05-06 Nanning Maple Leaf Pharmaceutical Co., Ltd. Composition of sodium channel blocking compound
US20020086036A1 (en) * 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
US20020161013A1 (en) * 2001-04-25 2002-10-31 Wex Medical Intrumentation Co., Ltd. Method of local anesthesia and analgesia
US20020198226A1 (en) * 2001-05-18 2002-12-26 Baoshan Ku Analgesic composition and method
US6780866B2 (en) * 2001-05-18 2004-08-24 Wex Medical Instrumentation Co., Ltd. Analgesic composition and method
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070280970A1 (en) * 2004-05-07 2007-12-06 Phytotox Limited Methods of Treating Wounds With Gonyautoxins
US20080021051A1 (en) * 2004-05-07 2008-01-24 Phytotox Limited Phycotoxins and Uses Thereof
US20080045553A1 (en) * 2004-05-07 2008-02-21 Phytotox Limited Transdermal Administration of Phycotoxins
US8377951B2 (en) 2004-05-07 2013-02-19 Phytotox Limited Transdermal administration of phycotoxins
US20090189226A1 (en) * 2008-01-28 2009-07-30 Yasue Yamamoto Electrical fuse circuit

Also Published As

Publication number Publication date
BR0214126A (en) 2004-10-13
JP2011068649A (en) 2011-04-07
CA2466697A1 (en) 2003-06-12
CA2466697C (en) 2013-09-24
EP1443932B1 (en) 2012-12-26
EA006739B1 (en) 2006-04-28
MXPA04004543A (en) 2005-03-31
ZA200403765B (en) 2005-07-27
US9301958B2 (en) 2016-04-05
AU2002348370B8 (en) 2008-05-01
ES2401570T3 (en) 2013-04-22
CN102349914B (en) 2015-01-28
JP2005515203A (en) 2005-05-26
JP5331959B2 (en) 2013-10-30
US20140163051A1 (en) 2014-06-12
IL161949A0 (en) 2005-11-20
EA200400670A1 (en) 2004-10-28
CN102349914A (en) 2012-02-15
PL370686A1 (en) 2005-05-30
US8871763B2 (en) 2014-10-28
HUP0402268A2 (en) 2005-02-28
NZ533309A (en) 2006-03-31
NO20042475L (en) 2004-06-14
WO2003047589A1 (en) 2003-06-12
EP1443932A1 (en) 2004-08-11
US20030100574A1 (en) 2003-05-29
KR20040066816A (en) 2004-07-27
US20140221407A1 (en) 2014-08-07
WO2003047589A8 (en) 2004-06-24
AU2002348370B2 (en) 2008-04-17
KR20100135884A (en) 2010-12-27
EP1443932A4 (en) 2007-11-28
US8889681B2 (en) 2014-11-18
AU2002348370A1 (en) 2003-06-17
CN1585642A (en) 2005-02-23
US20120238592A1 (en) 2012-09-20

Similar Documents

Publication Publication Date Title
US8871763B2 (en) Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm- related clinical pathologies
US6197830B1 (en) Method for achieving relief from sympathetically mediated pain
AU2005244096B2 (en) Transdermal administration of phycotoxins
US9107925B2 (en) Sodium channel blocker for treatment of loss of superficial sensitivity
RU2289417C1 (en) Method for biological skin rejuvenation
CN115942934A (en) Preventive or therapeutic agent for porphyria
US20030064932A1 (en) Methods of treatment comprising administration of Substance P
BRPI0214126B1 (en) Pharmaceutical composition for interfering with neuronal transmission, and preparation for facial rejuvenation
US20100273715A1 (en) Use of a peptide and an analgesic pharmaceutical agent
US5176912A (en) Method of treating psoriasis
EP4230207A1 (en) Amiloride for use in the topical treatment of somatosensory impairments
Wirtschafter et al. Botulinum toxin injections for treatment of blepharospasm and hemifacial spasm
Andre An easy and effective local anaesthesia for treating palmar hyperhidrosis with botulinum toxin injections: the Cry-ac system.
West properly and after being worn for days, are unlikely to prove disturbing. They do not interfere with ordinary con¬

Legal Events

Date Code Title Description
AS Assignment

Owner name: PHYTOTOX S.A., CHILE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WILSON, NESTOR ANTONIO LAGOS;REEL/FRAME:018119/0385

Effective date: 20021114

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: PHYTOTOX LIMITED, BERMUDA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PHYTOTOX S.A.;REEL/FRAME:033060/0079

Effective date: 20050506